-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。当社は、12ヶ月目標株価を520ドルに据え置きます。これは、バークシャー・ハサウェイの株価を、2027年の営業利益予想23.36ドル(本日0.59ドル下方修正)の22.3倍、2026年の営業利益予想21.76ドル(本日0.49ドル下方修正)の24倍と評価するものです。これは、過去3年間の平均予想PER23倍を上回っています。バークシャーの2026年第1四半期の営業利益は5.26ドル(前年同期は4.47ドル)となり、当社の予想5.10ドル、市場コンセンサス予想5.05ドルを上回りました。営業収益は4.4%増加しました。当社は、2026年の営業収益成長率予測を3%から7%に据え置いています。税引前営業利益は、利益率が5.6%から13%に拡大したことで2倍以上に増加しましたが、GEICOの保険引受結果は悪化し、コンバインド・レシオは79.8%から87.3%に上昇しました。CEOのグレッグ・エイベルは、初の年次株主総会でバークシャーの買収戦略と自社株買い方針を改めて表明しましたが、あらかじめ定められた資本配分については確約しませんでした。現在の水準では、配当なしの株価は適正に評価されていると考えています。
Related Articles
Telix Pharmaceuticals' Investigational Imaging Agent May Potentially Diagnose a Range of Kidney Cancers
Telix Pharmaceuticals' (ASX:TLX) investigational imaging agent TLX250-Px has the potential to help diagnose kidney cancers beyond just clear cell renal cell carcinoma, or ccRCC, the company said Tuesday, citing an independent analysis published in the European Urology scientific journal.The analysis of phase three trial data showed that positive PET scan findings were "highly predictive" of malignancy overall, including in non-clear cell renal cell carcinoma, with a reported positive predictive value of 98%, the company said."Essentially all false-positives for ccRCC in the ZIRCON study have now been shown to be other malignant kidney cancer subtypes, reducing the risk of overtreatment and further supporting clinical adoption," said Telix Group Chief Medical Officer David Cade.
Huajin International Chairman, CEO Face Consumption Restriction Order
Huajin International (HKG:2738) said its chairman and chief executive were subject to a consumption restriction order due to the alleged nonpayment of amounts owed, according to a Hong Kong bourse filing Tuesday.The company's chairman Xu Songqing and chief executive Chen Chunniu have been subject to the consumption restriction order, effective Nov. 25.The case stems from the alleged non-payment of 130 million yuan by two of the company's units Jiangmen Huamu Metals and Jiangmen Huajin Metal Product, under a finance lease arrangement. As of April 30, 16.4 million yuan was still owed to the creditors.Both Xu and Chen have been negotiating with creditors to resolve the matter and the company expects to reach a settlement by the end of August.
Tata Chemicals' Consolidated Loss Widens in Fiscal Q4
Tata Chemicals' (NSE:TATACHEM, BOM:500770) consolidated attributable loss widened to 21.3 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 1.56 billion rupees a year ago.Loss per share grew to 83.68 rupees compared with a loss per share of 2.19 rupees a year earlier, the chemicals manufacturer said in a filing to the Indian bourses on Monday.Revenue from operations in fiscal Q4 declined to 34.4 billion rupees from 35.1 billion rupees a year ago. This was lower than the 34.8 billion rupees estimated by analysts polled by Visible Alpha.The company's board recommended a dividend of 11 rupees per share for the financial year ended March 31.